| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $753K | +150.2% | — |
| Cost of Revenue | $260K | +22.1% | — |
| R&D Expense | $17.3M | -21.5% | -24.7% |
| SG&A Expense | $7.6M | -2.5% | +4.1% |
| Operating Income | -$24.4M | +18.0% | +19.3% |
| Income Tax | $0 | — | — |
| Net Income | -$17.5M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $19.5M | -48.8% | -5.3% |
| Accounts Receivable | $1.1M | +173.6% | — |
| Inventory | $18.4M | +66.4% | — |
| Current Assets | $41.4M | -20.1% | +79.7% |
| Total Assets | $91.5M | -34.1% | -20.3% |
| Current Liabilities | $25.6M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$78.9M | — | — |
| Capital Expenditures | $845K | — | — |
| Investing Cash Flow | -$845K | — | — |
| Financing Cash Flow | $4.3M | — | — |
| Free Cash Flow | -$79.8M | — | — |
| +55.3% |
| EPS (Basic) | -$0.11 | +54.2% | +66.7% |
| EPS (Diluted) | -$0.11 | +54.2% | +66.7% |
| +21.3% |
| +22.2% |
| Total Liabilities | $96.3M | -28.6% | -46.1% |
| Stockholders' Equity | -$4.8M | -217.3% | +92.5% |